Nanoscope Therapeutics Expands Clinical and CMC Leadership Team with Gene Therapy Pharma Experience

DALLAS, Nov. 7, 2022 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today announced that the Company has expanded its clinical and Chemistry, Manufacturing and Controls (CMC) team with the appointments of Jean Chang, as VP of Clinical Operations and Victor Adeniyi as Senior Director of CMC.

Read More: PRNewswireNews - Jornalwebdigital